arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bluejay Diagnostics, Inc.

BJDX
$0.96 ▲ +0.02 (+2.33%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bluejay Diagnostics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -19.7% ↗
FCF / Share $-0.79 ↗
Trailing P/E —
Price / Book 0.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-1.92M
↓ -2.9% —
FCF / Share Free cash flow per share
$-0.79
↑ +51.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality ↓
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters